Literature DB >> 12598156

Churg-Strauss syndrome.

Imre Noth1, Mary E Strek, Alan R Leff.   

Abstract

Churg-Strauss syndrome is a rare diffuse vasculitis that is almost invariably accompanied by severe asthma. Although overall prognosis is good, and treatment with prednisone alone or in combination with immunosuppressive drugs is usually successful, severe asthma typically persists. Diffuse organ involvement of Churg-Strauss syndrome, especially cardiovascular and rare involvement of the CNS and renal system, suggests a poorer prognosis than usual, and can be fatal. The cause of Churg-Strauss syndrome is unknown, but its characteristic histological findings and association with asthma distinguish it from other vasculitides. Controversy surrounds the use of asthma drugs-especially antileukotrienes--and development of the disorder. We review the epidemiological evidence for an association of drug treatment with Churg-Strauss syndrome, the diverse diagnostic and pathological criteria for this syndrome, and treatment options.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12598156     DOI: 10.1016/S0140-6736(03)12518-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  81 in total

1.  Initial neuro-ophthalmological manifestations in Churg-Strauss syndrome.

Authors:  Anne-Evelyne Vallet; Adrien Didelot; Fitsum Guebre-Egziabher; Martine Bernard; François Mauguière
Journal:  BMJ Case Rep       Date:  2010-10-12

Review 2.  [Childhood vasculitis].

Authors:  J B Kümmerle-Deschner; J Thomas; S M Benseler
Journal:  Z Rheumatol       Date:  2015-12       Impact factor: 1.372

3.  Churg-Strauss syndrome triggered by hyposensitization to Alternaria fungus.

Authors:  C Serna-Candel; O Moreno-Perez; V Soriano; A Martínez
Journal:  Clin Rheumatol       Date:  2007-08-03       Impact factor: 2.980

4.  Acute painless monocular visual loss due to central retinal artery occlusion in a patient with Churg-Strauss vasculitis.

Authors:  Ioanna Skrapari; Eleftheria Kagkelari; Evangelos Charitatos; Catherine Pantelidaki; Theodoros Gounaris; Evagelia Sioula
Journal:  Clin Rheumatol       Date:  2007-08-04       Impact factor: 2.980

5.  A case of Churg-Strauss syndrome associated with antiphospholipid antibodies.

Authors:  Katalin Ferenczi; Timothy Chang; Melissa Camouse; Rujing Han; Robert Stern; Joseph Willis; Kevin D Cooper; Anita C Gilliam
Journal:  J Am Acad Dermatol       Date:  2006-12-18       Impact factor: 11.527

6.  Eosinophilic tumor in a patient with bronchial asthma receiving pranlukast.

Authors:  Toru Watanabe; Yasufumi Iinuma; Shin-ichi Naito; Koju Nitta
Journal:  Eur J Pediatr       Date:  2006-08-17       Impact factor: 3.183

7.  [A patient with Churg-Strauss syndrome presenting as Guillain-Barré syndrome].

Authors:  M Djukic; H Schmidt; C Mazurek; F König; S Schweyer; R Nau
Journal:  Nervenarzt       Date:  2008-04       Impact factor: 1.214

Review 8.  Postpartum Churg-Strauss syndrome with severe cardiac involvement: description of a case and review of the literature.

Authors:  Domenico Corradi; Roberta Maestri; Fabio Facchetti
Journal:  Clin Rheumatol       Date:  2009-02-24       Impact factor: 2.980

9.  Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.

Authors:  Beverley R Twaites; Lynda V Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 10.  High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.

Authors:  Valeria Chirico; Antonio Lacquaniti; Vincenzo Salpietro; Caterina Munafò; Maria Pia Calabrò; Michele Buemi; Teresa Arrigo; Carmelo Salpietro
Journal:  Eur J Pediatr       Date:  2014-05-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.